Bristol-Myers Squibb and AstraZeneca’s joint diabetes effort, the pill dapagliflozin, although successful in a two-year study, might be linked to bladder and breast cancer, according to the U.S. Food and Drug Administration (FDA). Medical News Today said the agency is still deciding on whether or not to approve dapagliflozin and is expected to make its final [...]